Total VTE · 17,802 patients with low to normal levels of low density lipoprotein (LDL) cholesterol (< 130 mg/dL)
Statin probably leads to lower all cases of VTE compared with placebo (moderate certainty).
1 finding from 1 review
Pulmonary embolism · 17,802 patients with low to normal levels of low density lipoprotein (LDL) cholesterol (< 130 mg/dL)
1 finding from 1 review
Deep vein thrombosis · 17,802 patients with low to normal levels of low density lipoprotein (LDL) cholesterol (< 130 mg/dL)
1 finding from 1 review
Any MI · 17,802 patients with low to normal levels of low density lipoprotein (LDL) cholesterol (< 130 mg/dL)
Statin probably leads to lower any MI compared with placebo (moderate certainty).
1 finding from 1 review
Stroke · 17,802 patients with low to normal levels of low density lipoprotein (LDL) cholesterol (< 130 mg/dL)
Statin probably leads to lower any stroke compared with placebo (moderate certainty).
1 finding from 1 review
Death · 17,802 patients with low to normal levels of low density lipoprotein (LDL) cholesterol (< 130 mg/dL)
Statin probably leads to lower death compared with placebo (moderate certainty).
1 finding from 1 review
Any serious adverse event · 17,802 patients with low to normal levels of low density lipoprotein (LDL) cholesterol (< 130 mg/dL)
Statin showed no clear difference in any serious adverse event compared with placebo (moderate certainty).
1 finding from 1 review
Intervention not reported
Major cardiovascular events · adults with chronic kidney disease
The intervention showed no clear difference in major cardiovascular events (high certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality · adults with chronic kidney disease
The intervention showed no clear difference in all‐cause mortality (moderate certainty).
1 finding from 1 review
Intervention not reported
Cardiovascular mortality · adults with chronic kidney disease
The intervention showed no clear difference in cardiovascular mortality (moderate certainty).
1 finding from 1 review